JP2009529333A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529333A5
JP2009529333A5 JP2008558560A JP2008558560A JP2009529333A5 JP 2009529333 A5 JP2009529333 A5 JP 2009529333A5 JP 2008558560 A JP2008558560 A JP 2008558560A JP 2008558560 A JP2008558560 A JP 2008558560A JP 2009529333 A5 JP2009529333 A5 JP 2009529333A5
Authority
JP
Japan
Prior art keywords
composition
epha5
treated
peptide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008558560A
Other languages
English (en)
Japanese (ja)
Other versions
JP5167155B2 (ja
JP2009529333A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/063736 external-priority patent/WO2007104062A2/en
Publication of JP2009529333A publication Critical patent/JP2009529333A/ja
Publication of JP2009529333A5 publication Critical patent/JP2009529333A5/ja
Application granted granted Critical
Publication of JP5167155B2 publication Critical patent/JP5167155B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008558560A 2006-03-09 2007-03-09 ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 Expired - Fee Related JP5167155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78089306P 2006-03-09 2006-03-09
US60/780,893 2006-03-09
PCT/US2007/063736 WO2007104062A2 (en) 2006-03-09 2007-03-09 Compositions and methods based on peptide binding profiling

Publications (3)

Publication Number Publication Date
JP2009529333A JP2009529333A (ja) 2009-08-20
JP2009529333A5 true JP2009529333A5 (https=) 2011-06-30
JP5167155B2 JP5167155B2 (ja) 2013-03-21

Family

ID=38475889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558560A Expired - Fee Related JP5167155B2 (ja) 2006-03-09 2007-03-09 ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法

Country Status (6)

Country Link
US (3) US7781565B2 (https=)
EP (2) EP2002036A4 (https=)
JP (1) JP5167155B2 (https=)
AU (1) AU2007222991A1 (https=)
CA (1) CA2645277A1 (https=)
WO (1) WO2007104062A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9575070B2 (en) * 2001-12-04 2017-02-21 Wayne State University Neoepitope detection of disease using protein arrays
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
ITTO20060852A1 (it) * 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
US8722851B2 (en) * 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
JP2009126811A (ja) * 2007-11-22 2009-06-11 Kyoto Univ 合成ペプチド及びその利用
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
EP2444101A1 (en) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
WO2012170975A1 (en) * 2011-06-10 2012-12-13 The United States Of America As Representrd By The Secretary Of The Navy Nano-encapsulated therapeutics for controlled treatment of infection and other diseases
CN103764668B (zh) * 2011-07-09 2016-08-17 加利福尼亚大学董事会 白血病干细胞靶向配体及应用方法
EP2756002A4 (en) * 2011-09-16 2015-04-08 Univ Texas COMPOSITIONS AND METHODS RELATED TO THE REPAIR OF DNA DAMAGES
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
EP2838547B1 (en) * 2012-04-16 2019-09-04 Lubrizol Advanced Materials, Inc. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
CN103387603B (zh) * 2012-05-08 2015-07-15 复旦大学 一种rtn4b相关多肽及其制备与应用
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
DK3456734T3 (da) 2012-10-04 2022-04-19 Res Found Dev Serinproteasemolekyler og behandlinger
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
AU2014306592B2 (en) 2013-08-14 2019-04-04 Bristol-Myers Squibb Company Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
CN103804470B (zh) * 2014-01-22 2016-08-17 深圳市奥尼克斯基因技术有限公司 一种特异性靶向肿瘤淋巴管的新型多肽tmvp1的获得及应用
CA2993823C (en) 2015-07-28 2024-01-02 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
JP6839447B2 (ja) * 2015-10-01 2021-03-10 国立大学法人 新潟大学 胆道癌に特異的な集積性を有するペプチド及びその使用
CA3014921A1 (en) 2016-02-16 2017-08-24 Research Development Foundation Sortase-modified molecules and uses thereof
WO2018102762A1 (en) 2016-12-02 2018-06-07 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
EP2028187A1 (en) 2000-09-08 2009-02-25 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
US20040048243A1 (en) 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7718776B2 (en) * 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
EP1369482A1 (en) 2002-06-07 2003-12-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target genes for the diagnosis and treatment of cancer
DK1709081T3 (da) * 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
EP1755686A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
WO2006010070A2 (en) * 2004-07-10 2006-01-26 Board Of Regents, The University Of Texas System Compositions and methods related to peptides that selectively bind leukemia cells
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY

Similar Documents

Publication Publication Date Title
JP2009529333A5 (https=)
Seng et al. Biological and cytoselective anticancer properties of copper (II)-polypyridyl complexes modulated by auxiliary methylated glycine ligand
JP2007530553A5 (https=)
HRP20190494T1 (hr) Pro-koagulantski spojevi i postupci njihove uporabe
RU2755728C2 (ru) Новый конъюгат аманитина
FI2884999T4 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten
WO2016077840A3 (en) Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
JP2022540333A5 (https=)
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
JP2018522061A5 (https=)
Bergamo et al. Distinct effects of dinuclear ruthenium (III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
JP6483804B2 (ja) 新規なｈｄｍｘ阻害剤およびガン治療のためのその使用
GB0524477D0 (en) Isolated T cell receptors which specifically bind to vygfvracl-hla-24
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
Chiririwa et al. Synthesis, characterisation and in vitro evaluation of platinum (II) and gold (I) iminophosphine complexes for anticancer activity
ES2532666T3 (es) Compuestos y métodos para el tratamiento del cáncer
WO2014023063A1 (zh) 一种高效端粒酶抑制剂及其在抗肿瘤药物中的应用
Igarashi et al. Effectiveness of two novel anionic and cationic platinum complexes in the treatment of osteosarcoma
CN107375298B (zh) 手性金属超分子化合物在制备抗肿瘤干细胞药物中的应用
MX2009006003A (es) Composicion que contiene derivados de aurona con fines de diagnostico.
KR20250033281A (ko) 다각적 화학요법을 위한 전구약물 키트
Renfrew Ruthenium (II) arene compounds as versatile anticancer agents
CN102070615B (zh) 氮氧自由基抗肿瘤药物